Thrombosis in IBD in the Era of JAK Inhibition - Université de Lorraine
Article Dans Une Revue Current Drug Targets Année : 2020

Thrombosis in IBD in the Era of JAK Inhibition

Résumé

Patients with inflammatory bowel diseases (IBD) have an increased risk of thrombosis. The interaction between inflammation and coagulation has been extensively studied. It is well-known that some drugs can influence the haemostatic system, but several concerns on the association between therapies and increased risk of thrombosis remain open. While biologics seem to have a protective role against thrombosis via their anti-inflammatory effect, some concerns about an increased risk of thrombosis with JAK inhibitors have been raised. We conducted a literature review to assess the association between biologics/small molecules and venous/arterial thrombotic complications. An increased risk of venous and arterial thrombosis was found in patients treated with corticosteroids, whereas anti-TNF were considered protective agents. No thromboembolic adverse event was reported with vedolizumab and ustekinumab. In addition, thromboembolic events rarely occurred in patients with ulcerative colitis (UC) after therapy with tofacitinib. The overall risk of both venous and arterial thrombosis was not increased based on the available evidence. Finally, in the era of JAK inhibitors, treatment should be individualized by evaluating the pre-existing potential thrombotic risk balanced with the intrinsic risk of the medication used.
Fichier non déposé

Dates et versions

hal-04214609 , version 1 (22-09-2023)

Identifiants

Citer

Virginia Solitano, Gionata Fiorino, Ferdinando d'Amico, Laurent Peyrin-Biroulet, Silvio Danese. Thrombosis in IBD in the Era of JAK Inhibition. Current Drug Targets, 2020, 22 (1), pp.126-136. ⟨10.2174/1389450121666200902164240⟩. ⟨hal-04214609⟩
8 Consultations
0 Téléchargements

Altmetric

Partager

More